IACH Focus on Leukemia 2020 | Adding ATG to post-transplantation cyclophosphamide
Didier Blaise, MD, PhD, Paoli-Calmettes Institute, Marseille, France, discusses adding anti-thymocyte globulin (ATG) to post-transplantation cyclophosphamide in haploidentical stem-cell transplantation. Post-transplantation cyclophosphamide has become standard prophylaxis of GvHD. Dr Blaise discusses the possibility of adding ATG to post-transplantation cyclophosphamide to further reduce the incidence of GVHD. The results are promising, however, studies are in the early stages and cannot currently suggest an improvement. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
Disclosures
Meeting registration, travels and accommodations funded by pharmaceutical companies: Jazz Pharmaceuticals, Sanofi, Pierre Fabre medicaments, Molmed
Personal or familial shares in the capital of pharmaceutical companies: None
Personal fees from pharmaceutical companies: Molmed
